Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cardiai Technologies has 2 pending office actions in Biotechnology & Pharmaceuticals. These matters are assigned to 2 distinct examiners and a pair of art units. WILLIAMS, EMMALEE RAE is the busiest examiner, with 1 pending office action. The distribution of the pending office actions across separate art units suggests technical diversity in the pending matters.
With 2 pending office actions and 2 distinct examiners, the company is navigating two separate examination paths. WILLIAMS, EMMALEE RAE is the busiest examiner with 1 pending office action, which is the same workload as the other official. The fact that the cases are in separate art units indicates that the applications cover different technical aspects of Biotechnology & Pharmaceuticals.
This separation into 2 distinct art units requires the company to address the specific technical standards and procedural rules of each group independently. Practitioners should prepare for different examiner perspectives while navigating the unique rules of the art units involved. The parity between actions and examiners ensures that no single individual has a dominant influence over the current portfolio. This structure allows for a tailored approach for each official to ensure successful prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHHAY, BONIRATH | 1 | 62.5% | +0.0% |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18646980 | METHOD OF DIAGNOSING A CONDITION USING MICROBIOME DATA | CHHAY, BONIRATH | 1645 | §103§112DP | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCardiai Technologies has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Bonirath Chhay has the most, with 1 of Cardiai Technologies's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.